



PCT/GB 2003/003327



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road

Newport
South Wales
NP10 800

REC'D 03 SEP 2003

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Stephen Hordley


Dated

19 August 2003

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

BEST AVAILABLE COPY

An Executive Agency of the Department of Trade and Industry



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference **GBP86385**

2. Patent application number
(The Patent Office will fill in this part)

3 Full name, address and postcode of the or of each applicant (underline all surnames)

Pharma Mar, S.A.,
Calle de la Calera 3
Poligono Industrial de Tres Cantos
Tres Cantos
E-28760 Madrid
Spain

0217638.6

30 JUL 2002

4381141002

Patents ADP number (if you know it)

If the applicant is a corporate body, give the country/state of its incorporation

Spain

4. Title of the invention **TOTAL SYNTHESIS OF MYRIAPORONES**

5. Name of your agent (if you have one)
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Marks & Clerk
57 - 60 Lincolns Inn fields
London WC2A 3LS

Patents ADP number (if you know it)

18001

6.If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application No
(if you know it)

Date of filing
(day / month / year)

7.If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:
a) any applicant named in part 3 is not an inventor, or
b) there is an inventor who is not named as an applicant, or
c) any named applicant is a corporate body.
See note (d))

Yes

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form 0
Description 15
Claim(s)
Abstract
Drawing(s)



10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents (please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

Marks & Clerk

Date: 30 July 2002

12. Name and daytime telephone number of person to contact in the United Kingdom


GB Patent Filings
0207 400 3000

TOTAL SYNTHESIS OF MYRIAPORONES

The present invention relates to antitumoral compounds and their synthesis, and in particular the total synthesis of miryaporones.

BACKGROUND OF THE INVENTION


Miryaporones are a new class of marine, polyketide-derived isolated from the bryozoan *Myriapora truncata*.



Miryaporones are disclosed to have antitumor activity. The complete structure for these related compounds was given by K. L. Rinehart et al, *J. Nat. Prod.* **1995**, *58*, 344 and U.S. Patent No. 5,514,708, 1996. Compound 4 is an equilibrium mixture between the free hydroxy ketone and the hemiketal 3.

SUMMARY OF THE INVENTION

In a first aspect the present invention is directed to compounds of general formula 5.



5

wherein the substituent groups defined by R are each independently selected from the group consisting of H, SiR'₃, SOR', SO₂R', C(=O)R', C(=O)OR', C(=O)NR', substituted or unsubstituted: C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, aryl, heteroaryl or aralkyl;

wherein each of the R' groups is independently selected from the group consisting of H, OH, NH₂, halogen, substituted or unsubstituted: C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, aryl, heteroaryl or aralkyl;

wherein each of the R groups may be joined into a carbocyclic or heterocyclic system;


wherein the chiral centers marked with * has the R or the S configuration.

In another aspect the present invention is directed to the synthesis of the compounds of formula 5 as defined above, and to the intermediates used in such a synthetic process.

Another embodiment of the present invention is a pharmaceutical composition comprising the compounds of formula 5 or an intermediate of their synthesis and a pharmaceutically acceptable carrier.


Another embodiment of the present invention is the use of compounds of formula 5 as antitumor agents.

The compounds of the present invention can be synthetically prepared from the intermediate compound 6 described by W. R. Roush et al., *Org. Lett.* 1999, 1, 95.



6


The method of producing compounds of formula 5 is showed in the next Scheme.



The present invention will be further explained with the following examples:


EXPERIMENTAL PART

Example 1: Compound 7




To a solution of 6 (3.51 g, 7.8 mmol) in CH_2Cl_2 (40 mL) was added imidazole (1.59 g, 23.4 mmol) and TBSCl (1.76 g, 11.7 mmol) at 23 °C. The reaction mixture was stirred at 23 °C for 3 h. HCl 0.1 N was added until pH= 4-5, and the mixture was extracted with CH_2Cl_2 (2x). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (Hex:EtOAc, 10:1) to obtain compound 7 (3.44 g, 78%) as a colourless oil. ^1H NMR (300 MHz, CDCl_3) δ 7.23 (d, J = 8.7 Hz, 2H), 6.86 (d, J = 8.7 Hz, 2H), 5.83 (m, 1H), 4.99 (dd, J = 10.5, 1.8 Hz, 1H), 4.86 (dd, J = 17.4, 2.1 Hz, 1H), 4.42 (s, 2H), 3.80 (s, 3H), 3.44 (m, 2H), 3.33 (d, J = 6.6 Hz, 1H), 2.47 (d, J = 9.6 Hz, 1H), 2.24 (m, 1H), 1.75 (m, 1H), 1.08 (d, J = 6.6 Hz, 3H), 0.91 (s, 9H), 0.88 (s, 9H), 0.13 (s, 3H), 0.04 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 159.1, 136.2, 130.3, 129.1, 117.1, 113.7, 72.9, 72.6, 64.9, 64.6, 63.9, 55.2, 51.3, 33.1, 25.9, 25.8, 18.2, 18.1, 14.9, 13.3, -4.2, -5.3, -5.4, -5.5. MS (ESI) m/z : 587 ($M+23$)⁺. $[\alpha]_D^{25}$ -9.5 (c 0.52, CH_2Cl_2).

Example 2: Compound 8



To a solution of 7 (0.86 g, 1.52 mmol) in THF:H₂O (10:1, 22 mL) was added NMO (0.623 g, 5.32 mmol) and OsO_4 (4.56 mL, 0.456 mmol, 0.1 M in $t\text{BuOH}$) at 23 °C and the reaction mixture was stirred at 23 °C overnight. Florisil (6 g), NaHSO_3 (6 g), and EtOAc (100 mL) were added and the mixture was stirred vigorously during 30 min. The mixture was filtered through a pad of Celite, and the filtrate was concentrated to provide the corresponding diol. To a solution of this diol in THF (10 mL) was added a solution of NaIO_4 (1.95 g, 9.12 mmol) in H₂O (8 mL) at 0 °C and the mixture was stirred at 23 °C for 1 h. The reaction was quenched by addition of a saturated aqueous solution of NH_4Cl (20 mL) and then, extracted with CH_2Cl_2 (2x20 mL). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (Hex:EtOAc, 10:1) to afford compound 8 (0.67 g, 78%) as a colourless oil. ^1H NMR (300 MHz, CDCl_3) δ 9.67 (d, J = 3.0 Hz, 1H), 7.20 (d, J = 8.4 Hz, 2H), 6.84 (d, J = 8.4 Hz, 2H), 4.38 (m, 2H), 3.84 (dd, J = 10.2, 5.1 Hz, 1H), 3.80 (s, 3H), 3.69 (m, 2H), 3.41 (dd, J = 9.3, 5.1 Hz, 1H), 3.31 (t, J = 9.0 Hz, 1H), 2.59 (d, J = 9.3 Hz, 1H), 2.50 (m, 1H), 1.81 (m, 1H), 1.30 (s, 3H), 1.06 (d, J = 6.3 Hz, 3H), 0.86 (s, 18H), 0.14 (s, 3H), 0.04 (s, 3H), 0.02 (s, 3H), 0.01 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 203.8, 159.5, 130.3, 129.4, 114.0, 76.5, 73.2, 73.0, 65.1, 64.0, 60.1, 57.9, 55.4, 33.6, 26.0, 26.0, 18.3, 15.0, 13.0, -4.0, -5.2, -5.3, -5.5. MS (ESI) m/z : 589 ($M+23$)⁺. $[\alpha]_D^{25}$ -11.6 (c 0.50, CH_2Cl_2).


Example 3: Compound 9



Compound 9 was prepared following the procedure described by D. A. Evans et al. *J. Am. Chem. Soc.* 1984, 106, 4261-4263. ^1H NMR (300 MHz, CDCl_3) δ 7.21 (m, 1H), 7.12 (m, 1H),


4.44 (m, 1H), 4.20 (m, 2H), 2.36 (m, 1H), 1.91 (dd, $J = 6.6, 1.2$ Hz, 3H), 0.88 (d, $J = 6.9$ Hz, 3H), 0.83 (d, $J = 6.9$ Hz, 3H).

Example 4: Compound 10



To a solution of **9** (11.2 g, 56.8 mmol) in CH_2Cl_2 (150 mL) was added Bu_2BOTf (62.5 mL, 62.4 mmol) and Et_3N (11.1 mL, 79.5 mmol) at -78°C . The reaction mixture was stirred 1 h at -78°C , 15 min at 0°C and recooled at -78°C . A solution of **8** (10.7 g, 18.9 mmol) in CH_2Cl_2 (50 mL) was cooled to 0°C . 50 mL of the solution of **9** was added over the solution of **8** at 0°C and the reaction mixture was stirred 1 h at 0°C . The addition was repeated twice in the following 2 hours. Then saturated aqueous solution of NH_4Cl (100 mL) was added and the reaction was extracted with CH_2Cl_2 (2x 120 mL). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (Hex:EtOAc, from 10:1 to 2:1) to afford compound **10** (10.1 g, 70%) as a colourless oil. ^1H NMR (300 MHz, CDCl_3) δ 7.19 (d, $J = 8.4$ Hz, 2H), 6.85 (d, $J = 8.4$ Hz, 2H), 5.93 (m, 1H), 5.41 (d, $J = 17.1$ Hz, 1H), 5.28 (d, $J = 9.3$ Hz, 1H), 4.92 (t, $J = 9.6$ Hz, 1H), 4.63 (dddd, $J = 9.3, 6.3, 5.1, 1.5$ Hz, 1H), 4.43 (s, 3H), 4.34 (m, 1H), 4.12 (m, 2H), 3.85 (m, 1H), 3.80 (s, 3H), 3.73 (m, 2H), 4.44 (m, 2H), 2.58 (d, $J = 9.3$ Hz, 1H), 2.30 (m, 1H), 1.81 (m, 1H), 1.38 (s, 3H), 1.10 (d, $J = 6.6$ Hz, 3H), 0.93 (s, 9H), 0.87 (s, 9H), 0.84 (d, $J = 7.5$ Hz, 3H), 0.80 (d, $J = 6.9$ Hz, 3H), 0.17 (s, 3H), 0.12 (s, 3H), 0.09 (s, 3H), 0.04 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 172.0, 159.0, 153.3, 135.3, 129.9, 128.6, 113.7, 77.4, 72.6, 71.0, 64.0, 63.4, 62.6, 59.8, 58.4, 58.0, 55.2, 51.2, 45.2, 40.1, 33.6, 26.7, 28.3, 27.8, 26.1, 25.8, 18.3, 17.9, 15.1, 14.6, 14.3, 13.1, -4.4, -5.4, -5.5, -5.6. MS (ESI) m/z : 786 ($M+23$) $^+$. $[\alpha]_D^{25} +3.1$ (c 0.53, CH_2Cl_2).


Example 5: Compound 11



To a solution of **10** (14.5 g, 18.9 mmol) in $\text{THF}:\text{H}_2\text{O}$ (5:1, 120 mL), LiBH_4 (94.6 mL, 189.2 mmol, 2.0 M in THF) was added at 0°C . The reaction mixture was stirred 1 h at 0°C and 2 h at 23°C . Saturated aqueous solution of NH_4Cl (100 mL) was added and the mixture was extracted with EtOAc (3x100 mL). The combined organic layers were washed with NaOH 1 N (2x100 mL), dried over Na_2SO_4 , filtered and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (Hex:EtOAc, 10:1) to afford **11** (7.99 g, 66%) as a colourless oil. ^1H NMR (300 MHz, CDCl_3) δ 7.22 (d, $J = 8.4$ Hz, 2H), 6.87 (d, $J = 8.4$ Hz, 2H), 5.84 (m, 1H), 5.21 (d, $J = 8.7$ Hz, 1H), 5.14 (d, $J = 17.4$ Hz, 1H), 4.42 (s, 2H), 4.19 (m, 1H), 3.84 (m, 1H), 3.80 (s, 3H), 3.75 (m, 1H), 3.61 (m, 2H), 3.48 (m, 2H), 3.36 (m, 2H), 2.53 (d, $J = 9.3$ Hz, 1H), 2.27 (m, 1H), 1.80 (m, 1H), 1.32 (s, 3H), 1.05 (d, $J = 6.9$ Hz, 3H), 0.91 (s, 9H), 0.88 (s, 9H), 0.15 (s, 3H), 0.09 (s, 3H), 0.05 (s, 3H), 0.04 (s,


3H). ^{13}C NMR (75 MHz, CDCl_3) δ 159.5, 137.6, 130.3, 129.4, 118.3, 114.0, 73.2, 73.0, 71.2, 64.9, 64.4, 60.4, 55.5, 51.1, 47.0, 33.5, 29.9, 26.4, 26.3, 26.0, 18.4, 18.2, 15.0, 14.0, -4.2, -5.1, -5.2. MS (ESI) m/z : 662 ($\text{M}+23$) $^+$.

Example 6: Compound 12a




To a solution of 11 (7.43 g, 11.6 mmol) in CH_2Cl_2 (100 mL) was added imidazole (3.16 g, 46.4 mmol) and TBSCl (3.48 g, 23.2 mmol) at 23 °C. The reaction mixture was stirred at 23 °C for 12 h. 0.1N HCl was added until pH= 4-5, and the reaction was extracted with CH_2Cl_2 (2x150 mL). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (Hex:EtOAc, from 10:1 to 4:1) to obtain compound 12a (8.47 g, 97%) as a colourless oil. ^1H NMR (300 MHz, CDCl_3) δ 7.22 (d, J = 8.6 Hz, 2H), 6.86 (d, J = 8.6 Hz, 2H), 5.86 (m, 1H), 5.07 (m, 2H), 4.41 (m, 2H), 4.29 (br s, 1H), 3.88 (m, 1H), 3.80 (s, 3H), 3.74 (m, 1H), 3.62 (m, 2H), 3.48 (m, 1H), 3.34 (d, J = 6.8 Hz, 2H), 3.17 (d, J = 4.9 Hz, 1H), 2.55 (d, J = 9.2 Hz, 1H), 2.26 (m, 1H), 1.78 (m, 2H), 1.32 (s, 3H), 1.06 (d, J = 6.6 Hz, 3H), 0.92 (s, 9H), 0.88 (s, 9H), 0.87 (s, 9H), 0.16 (s, 3H), 0.10 (s, 3H), 0.05 (s, 3H), 0.03 (s, 9H). ^{13}C NMR (75 MHz, CDCl_3) δ 159.4, 138.0, 130.5, 129.2, 117.1, 114.0, 77.4, 73.1, 72.8, 69.4, 65.0, 64.8, 64.5, 60.7, 55.4, 51.9, 46.9, 33.7, 29.9, 26.3, 26.2, 26.1, 18.6, 18.5, 18.1, 15.1, 13.5, -4.3, -5.0, -5.1, -5.2. MS (ESI) m/z : 775 ($\text{M}+23$) $^+$, 753 ($\text{M}+1$) $^+$.

Example 7: Compound 12b




To a solution of 12a (500 mg, 0.663 mmol) in CH_2Cl_2 (30 mL) was added Dess-Martin periodinane (562 mg, 1.32 mmol) at 23 °C. The reaction mixture was stirred at 23 °C for 3 h. Saturated aqueous solution of NaHCO_3 (30 mL) was added and the mixture was extracted with CH_2Cl_2 (3x 40 mL). The combined organic layers were dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (Hex:EtOAc, 10:1) to obtain compound 12b (414 mg, 83%) as a colourless oil. ^1H NMR (300 MHz, CDCl_3) δ 7.24 (d, J = 8.4 Hz, 2H), 6.87 (d, J = 8.4 Hz, 2H), 5.78 (m, 1H), 5.23 (m, 2H), 4.42 (dd, J = 16.2, 11.4, 2H), 4.02 (dd, J = 10.2, 4.8 Hz, 1H), 3.81 (s, 3H), 3.74 (m, 1H), 3.61 (m, 2H), 3.33 (m, 3H), 2.48 (d, J = 9.3 Hz, 1H), 1.77 (m, 1H), 1.29 (s, 3H), 1.06 (d, J = 6.6 Hz, 3H), 0.87 (s, 9H), 0.86 (s, 9H), 0.84 (s, 9H), 0.11 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H), 0.02 (s, 3H), -0.01 (s, 3H), -0.03 (s, 3H). ^{13}C NMR (75 MHz, CDCl_3) δ 209.2, 159.1, 134.3, 130.2, 129.0, 119.3, 113.7, 77.5, 72.7, 72.2, 64.3, 63.0, 62.3, 62.2, 61.1, 55.9, 55.2, 33.6, 29.7, 26.0, 25.9, 25.8, 18.2, 18.1, 15.0, 12.2, -4.5, -5.2, -5.3, -5.4, -5.4, -5.5. MS (ESI) m/z : 773 ($\text{M}+23$) $^+$.

Example 8: Compound 13a




To a solution of 12a (1.5 g, 1.99 mmol) in THF (30 mL) was added Et₃N (5.55 mL, 39.82 mmol), DMAP (24 mg, 0.119 mmol) and Ac₂O (1.88 mL, 19.91 mmol) at 0 °C. The reaction mixture was stirred at 23 °C for 12 h. Saturated aqueous solution of NaHCO₃ (50 mL) was added and the mixture was extracted with CH₂Cl₂ (3x50 mL). The combined organic layers were washed with 0.1N HCl (2x50 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (Hex:EtOAc, 10:1) to obtain compound 13a (1.12 g, 71%) as a colourless oil. ¹H NMR (300 MHz, CDCl₃) δ 7.23 (d, *J* = 8.5 Hz, 2H), 6.86 (d, *J* = 8.5 Hz, 2H), 5.66 (m, 1H), 5.48 (m, 1H), 5.09 (m, 2H), 4.42 (m, 2H), 3.80 (s, 3H), 3.60 (m, 2H), 3.46 (m, 2H), 3.34 (m, 4H), 2.61 (m, 1H), 2.48 (d, *J* = 9.1 Hz, 1H), 1.95 (s, 3H), 1.77 (m, 1H), 1.34 (s, 3H), 1.06 (d, *J* = 6.6 Hz, 3H), 0.91 (s, 9H), 0.88 (s, 9H), 0.86 (s, 9H), 0.11 (s, 3H), 0.05 (s, 3H), 0.03 (s, 6H), 0.01 (s, 3H), -0.01 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 169.8, 159.4, 136.7, 130.6, 129.3, 118.3, 114.0, 76.9, 73.0, 72.6, 70.6, 64.4, 59.9, 55.4, 52.5, 47.1, 33.4, 26.3, 26.1, 26.1, 21.4, 18.6, 18.3, 15.2, 13.3, -4.1, -4.9, -5.0, -5.1, -5.2, -5.2. MS (ESI) *m/z*: 817 (M+23)⁺, 812 (M+18)⁺.

Example 9: Compound 13b




To a solution of 12a (215 mg, 0.285 mmol) in THF (5 mL) was added Py (0.46 mL, 5.7 mmol), DMAP (53 mg, 0.427 mmol) and (CF₃CO)₂O (0.40 mL, 2.85 mmol) at 0 °C. The reaction mixture was stirred at 23 °C for 12 h. Saturated aqueous solution of NaHCO₃ (7 mL) was added and the reaction was extracted with CH₂Cl₂ (3x10 mL). The combined organic layers were washed with HCl 0.1N (2x4 mL), dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (Hex:EtOAc, 18:1) to obtain compound 13b (221 mg, 91%) as a colourless oil. ¹H NMR (300 MHz, CDCl₃) δ 7.22 (d, *J* = 8.7 Hz, 2H), 6.87 (d, *J* = 8.7 Hz, 2H), 5.75 (m, 1H), 5.65 (m, 1H), 5.09 (m, 2H), 4.42 (s, 2H), 3.81 (s, 3H), 3.47 (m, 8H), 2.78 (m, 1H), 2.51 (d, *J* = 9.0 Hz, 1H), 2.11 (m, 1H), 1.78 (m, 1H), 1.33 (s, 3H), 1.06 (d, *J* = 6.9 Hz, 3H), 0.91 (s, 9H), 0.88 (s, 18H), 0.12 (s, 3H), 0.06 (s, 3H), 0.03 (s, 3H), 0.01 (s, 6H), 0.00 (s, 3H). ¹³C NMR (75 MHz, CDCl₃) δ 159.2, 156.0 (d, *J*_{C-F} = 41.0 Hz), 134.6, 130.2, 129.1, 119.4, 113.8, 76.0, 75.4, 72.9, 72.7, 64.3, 64.0, 63.8, 59.3, 55.2, 51.6, 46.2, 33.1, 26.1, 25.9, 18.3, 18.0, 14.8, 14.1, 13.2, -4.5, -5.0, -5.4, -5.5, -5.6, -5.7. MS (ESI) *m/z*: 866 (M+18)⁺.

Example 10: Compound 14a




To a solution of 13a (2.25 g, 2.84 mmol) in THF:H₂O (70:30, 105 mL) was added NMO (1.16 g, 9.94 mmol) and OsO₄ (5.68 mL, 0.568 mmol, 0.1 M in ^tBuOH) at 23 °C and the reaction mixture was stirred at 23 °C overnight. Florisil (16 g), NaHSO₃ (16 g), and EtOAc (160 mL) were added and the mixture was stirred vigorously during 30 min. The mixture was filtered through a pad of Celite, and the filtrate was concentrated to provide the corresponding diol. This diol was dissolved in anhydrous Toluene (50 mL) and Pb(OAc)₄ (1.57 g, 3.55 mmol) was added at 0 °C, stirred for 30 min, filtered through a pad of Celite, washed with EtOAc and concentrated under reduced pressure. The residue was purified by flash column chromatography on silica gel (Hex:EtOAc, 20:1) to afford compound 14a (0.97 g, 43%) as a colourless oil. ¹H NMR (300 MHz, CDCl₃) δ 9.61 (d, *J* = 3.9 Hz, 1H), 7.22 (d, *J* = 8.5 Hz, 2H), 6.87 (d, *J* = 8.5 Hz, 2H), 5.56 (dd, *J* = 10.3, 6.6 Hz, 1H), 4.42 (s, 2H), 3.95 (m, 1H), 3.80 (s, 3H), 3.54 (m, 2H), 3.38 (d, *J* = 7.0 Hz, 2H), 3.24 (d, *J* = 6.8 Hz, 1H), 3.04 (m, 1H), 2.49 (d, *J* = 9.0 Hz, 1H), 1.98 (s, 3H), 1.79 (m, 1H), 1.31 (s, 3H), 1.06 (d, *J* = 6.8 Hz, 3H), 0.92 (s, 9H), 0.88 (s, 9H), 0.85 (s, 9H), 0.13 (s, 3H), 0.06 (s, 6H), 0.04 (s, 3H), 0.03 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 203.3, 170.1, 159.4, 130.4, 129.3, 114.0, 76.6, 73.1, 72.7, 69.1, 64.4, 63.9, 61.3, 60.0, 58.4, 55.4, 46.4, 33.4, 29.9, 26.4, 26.1, 26.0, 21.2, 18.6, 18.4, 18.3, 15.1, 12.8, -4.1, -5.0, -5.1, -5.2, -5.3, -5.4. MS (ESI) *m/z*: 819 (M+23)⁺.

Example 11: Compound 14b



To a solution of 13b (241 mg, 0.285 mmol) in THF:H₂O (70:30, 14 mL) was added NMO (117 mg, 1.0 mmol) and OsO₄ (0.85 mL, 0.085 mmol, 0.1 M in ^tBuOH) at 23 °C and the reaction mixture was stirred at 23 °C overnight. Florisil (1.5 g), NaHSO₃ (1.5 g), and EtOAc (30 mL) were added and the mixture was stirred vigorously. After 30 min, this mixture was filtered through a pad of Celite, and the filtrate was concentrated to provide the corresponding diol. This diol was dissolved in anhydrous Toluene (30 mL) and Pb(OAc)₄ (158 mg, 0.356 mmol) was added at 0 °C, stirred for 10 min, filtered through a pad of Celite, washed with EtOAc and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (Hex:EtOAc, 19:1) to afford compound 14b (128 mg, 53%) as a white solid. ¹H NMR (300 MHz, CDCl₃) δ 9.80 (d, *J* = 3.0 Hz, 1H), 7.20 (d, *J* = 8.7 Hz, 2H), 6.86 (d, *J* = 8.7 Hz, 2H), 4.66 (m, 1H), 4.40 (s, 2H), 3.86 (m, 2H), 3.80 (s, 3H), 3.69 (m, 2H), 3.62 (m, 2H), 3.36 (m, 2H), 2.59 (d, *J* = 9.3 Hz, 1H), 2.46 (m, 1H), 1.81 (m, 1H), 1.72 (m, 1H), 1.29 (s, 3H), 1.06 (d, *J* = 6.6 Hz, 3H), 0.92 (s, 6H), 0.87 (s, 6H), 0.85 (s, 6H), 0.16 (s, 3H), 0.11 (s, 3H), 0.06 (s, 6H), 0.01 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 205.4, 159.2, 130.0, 129.1, 113.7, 76.4, 72.9, 72.7, 68.0, 64.6, 63.9, 60.8, 60.1, 57.7, 55.2, 44.4, 33.5, 29.7, 26.1, 25.7, 18.3, 18.1, 17.8, 14.8, 12.9, -4.6, -5.3, -5.5, -5.5, -5.7, -5.7.

Example 12: Compound 14d



To a solution of **12a** (500 mg, 0.663 mmol) in THF:H₂O (70:30, 28 mL) was added NMO (273 mg, 2.32 mmol) and OsO₄ (1.33 mL, 0.132 mmol, 0.1 M in ^tBuOH) at 23 °C and the reaction mixture was stirred at 23 °C overnight. Florisil (3.5 g), NaHSO₃ (3.5 g), and EtOAc (60 mL) were added and the mixture was stirred vigorously. After 30 min, this mixture was filtered through a pad of Celite, and the filtrate was concentrated to provide the corresponding diol. This diol was dissolved in anhydrous Toluene (20 mL) and Pb(OAc)₄ (367 mg, 0.828 mmol) was added at 0 °C, stirred for 30 min, filtered through a pad of Celite, washed with EtOAc and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (Hex:EtOAc, 15:1) to afford compound **14d** (228 mg, 46%) as a colourless oil. ¹H NMR (300 MHz, CDCl₃) δ 9.80 (d, *J* = 3.0 Hz, 1H), 7.20 (d, *J* = 8.7 Hz, 2H), 6.85 (d, *J* = 8.7 Hz, 2H), 4.66 (m, 1H), .439 (s, 2H), 3.84 (m, 2H), 3.78 (s, 3H), 3.68 (m, 2H), 3.61 (m, 2H), 3.37 (m, 2H), 2.58 (d, *J* = 9.0 Hz, 1H), 2.44 (m, 1H), 1.82 (m, 1H), 1.72 (m, 1H), 1.29 (s, 3H), 1.05 (d, *J* = 6.6 Hz, 3H), 0.91 (s, 9H), 0.87 (s, 9H), 0.85 (s, 9H), 0.15 (s, 3H), 0.11 (s, 3H), 0.06 (s, 6H), 0.00 (s, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 205.3, 159.2, 130.0, 129.0, 113.7, 76.4, 72.8, 72.7, 67.9, 64.6, 63.9, 60.8, 60.1, 57.7, 55.1, 44.4, 33.5, 26.1, 25.7, 18.3, 18.1, 17.8, 14.8, 12.9, -4.6, -5.3, -5.5, -5.5, -5.7, -5.7.

Alkyl groups preferably have from 1 to 24 carbon atoms. One more preferred class of alkyl groups has 1 to about 12 carbon atoms, yet more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, and most preferably 1, 2, 3 or 4 carbon atoms. Another more preferred class of alkyl groups has 12 to about 24 carbon atoms, yet more preferably 12 to about 18 carbon atoms, and most preferably 13, 15 or 17 carbon atoms. Methyl, ethyl and propyl including isopropyl are particularly preferred alkyl groups in the compounds of the present invention. As used herein, the term alkyl, unless otherwise modified, refers to both cyclic and noncyclic groups, although cyclic groups will comprise at least three carbon ring members.

Preferred alkenyl and alkynyl groups in the compounds of the present invention have one or more unsaturated linkages and from 2 to about 12 carbon atoms, more preferably 2 to about 8 carbon atoms, still more preferably 2 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4

carbon atoms. The terms alkenyl and alkynyl as used herein refer to both cyclic and noncyclic groups, although straight or branched noncyclic groups are generally more preferred.

Preferred alkoxy groups in the compounds of the present invention include groups having one or more oxygen linkages and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms, and most preferably 1, 2, 3 or 4 carbon atoms.

Preferred alkylsulfinyl groups in the compounds of the present invention include those groups having one or more sulfoxide (SO) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfinyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred.

Preferred alkylsulfonyl groups in the compounds of the present invention include those groups having one or more sulfonyl (SO₂) groups and from 1 to about 12 carbon atoms, more preferably from 1 to about 8 carbon atoms, and still more preferably 1 to about 6 carbon atoms. Alkylsulfonyl groups having 1, 2, 3 or 4 carbon atoms are particularly preferred.

Preferred aminoalkyl groups include those groups having one or more primary, secondary and/or tertiary amine groups, and from 1 to about 12 carbon atoms, more preferably 1 to about 8 carbon atoms, still more preferably 1 to about 6 carbon atoms, even more preferably 1, 2, 3 or 4 carbon atoms. Secondary and tertiary amine groups are generally more preferred than primary amine moieties.

Suitable heterocyclic groups include heteroaromatic and heteroalicyclic groups. Suitable heteroaromatic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N,

O or S atoms and include, e.g., coumarinyl including 8-coumarinyl, quinolinyl including 8-quinolinyl, pyridyl, pyrazinyl, pyrimidyl, furyl, pyrrolyl, thienyl, thiazolyl, oxazolyl, imidazolyl, indolyl, benzofuranyl and benzothiazol. Suitable heteroalicyclic groups in the compounds of the present invention contain one, two or three heteroatoms selected from N, O or S atoms and include, e.g., tetrahydrofuranyl, tetrahydropyranyl, piperidiny, morpholino and pyrrolindinyl groups.

Suitable carbocyclic aryl groups in the compounds of the present invention include single and multiple ring compounds, including multiple ring compounds that contain separate and/or fused aryl groups. Typical carbocyclic aryl groups contain 1 to 3 separate or fused rings and from 6 to about 18 carbon ring atoms. Specifically preferred carbocyclic aryl groups include phenyl including substituted phenyl such as 2-substituted phenyl, 3-substituted phenyl, 2,3-substituted phenyl, 2,5-substituted phenyl, 2,3,5-substituted and 2,4,5-substituted phenyl, including where one or more of the phenyl substituents is an electron-withdrawing group such as halogen, cyano, nitro, alkanoyl, sulfinyl, sulfonyl and the like; naphthyl including 1-naphthyl and 2-naphthyl; biphenyl; phenanthryl; and anthracyl.

References herein to substituted groups in the compounds of the present invention refer to the specified moiety, typically alkyl or alkenyl, that may be substituted at one or more available positions by one or more suitable groups, e.g., halogen such as fluoro, chloro, bromo and iodo; cyano; hydroxyl; nitro; azido; alkanoyl such as a C1-6 alkanoyl group such as acyl and the like; carboxamido; alkyl groups including those groups having 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms and more preferably 1-3 carbon atoms; alkenyl and alkynyl groups including groups having one or more unsaturated linkages and from 2 to about 12 carbon or from 2 to about 6 carbon atoms; alkoxy groups having those having one or more oxygen linkages and from 1 to about 12 carbon atoms or 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those moieties having one or more thioether linkages and from 1 to about 12

carbon atoms or from 1 to about 6 carbon atoms; alkylsulfinyl groups including those moieties having one or more sulfinyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those moieties having one or more sulfonyl linkages and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; carbocyclic aryl having 6 or more carbons, particularly phenyl (e.g., R being a substituted or unsubstituted biphenyl moiety); and aralkyl such as benzyl; heterocyclic groups including heteroalicyclic and heteroaromatic groups, especially with 5 to 10 ring atoms of which 1 to 4 are heteroatoms, more preferably heterocyclic groups with 5 or 6 ring atoms and 1 or 2 heteroatoms or with 10 ring atoms and 1 to 3 heteroatoms.

Preferred R' groups are present in groups of formula R', COR' or OCOR' and include alkyl or alkenyl, that may be substituted at one or more available positions by one or more suitable groups, e.g., halogen such as fluoro, chloro, bromo and iodo, especially ω -chloro or perfluoro; aminoalkyl groups such as groups having one or more N atoms and from 1 to about 12 carbon atoms or from 1 to about 6 carbon atoms; carbocyclic aryl having 6 or more carbons, particularly phenyl; and aralkyl such as benzyl; heterocyclic groups including heteroalicyclic and heteroaromatic groups, especially with 5 to 10 ring atoms of which 1 to 4 are heteroatoms, more preferably heterocyclic groups with 5 or 6 ring atoms and 1 or 2 heteroatoms or with 10 ring atoms and 1 to 3 heteroatoms, the heterocyclic groups optionally being substituted with one or more of the substituents permitted for R' and especially amino such as dimethylamino or with keto.

Suitable halogen substituents in the compounds of the present invention include F, Cl, Br and I.

The invention provides new compounds which differ from the known myriaporones. The new compounds may differ isomerically or otherwise.

The invention also extends to equilibrium isomers of the compounds of formula 5, notably where a hydroxyketone forms a ketal.

In one class of compounds of this invention, the substituent at carbon 17 (see US 5514708 for numbering system) is not OH or OAc. More preferably, the substituent has at least 4, 5 or 6 carbon atoms and/or is not OH or OCOR'.

Another especially preferred embodiment of the present invention is pharmaceutical compositions useful as antitumor agents which contain as active ingredient a compound or compounds of the invention, as well as the processes for their preparation.

Examples of pharmaceutical compositions include any solid (tablets, pills, capsules, granules etc.) or liquid (solutions, suspensions or emulsions) with suitable composition or oral, topical or parenteral administration.

Administration of the compounds or compositions of the present invention may be any suitable method, such as intravenous infusion, oral preparation, intraperitoneal and intravenous preparation. We prefer that infusion times of up to 24 hours are used, more preferably 2-12 hours, with 2-6 hours most preferred. Short infusion times which allow treatment to be carried out without an overnight stay in hospital are especially desirable. However, infusion may be 12 to 24 hours or even longer if required. Infusion may be carried out at suitable intervals of say 2 to 4 weeks. Pharmaceutical compositions containing compounds of the invention may be delivered by liposome or nanosphere encapsulation, in sustained release formulations or by other standard delivery means.

The correct dosage of the compounds will vary according to the particular formulation, the mode of application, and the particular situs, host and tumour being treated. Other factors like age, body weight, sex,

diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account. Administration can be carried out continuously or periodically within the maximum tolerated dose.

The compounds and compositions of this invention may be used with other drugs to provide a combination therapy. The other drugs may form part of the same composition, or be provided as a separate composition for administration at the same time or a different time. The identity of the other drug is not particularly limited, and suitable candidates include:

- a) drugs with antimitotic effects, especially those which target cytoskeletal elements, including microtubule modulators such as taxane drugs (such as taxol, paclitaxel, taxotere, docetaxel), podophylotoxins or vinca alkaloids (vincristine, vinblastine);
 - b) antimetabolite drugs such as 5-fluorouracil, cytarabine, gemcitabine, purine analogues such as pentostatin, methotrexate);
 - c) alkylating agents such as nitrogen mustards (such as cyclophosphamide or ifosfamide);
 - d) drugs which target DNA such as the anthracycline drugs adriamycin, doxorubicin, pharmorubicin or epirubicin;
 - e) drugs which target topoisomerases such as etoposide;
 - f) hormones and hormone agonists or antagonists such as estrogens, antiestrogens (tamoxifen and related compounds) and androgens, flutamide, leuporelin, goserelin, cyprotone or octreotide;
-
- g) drugs which target signal transduction in tumour cells including antibody derivatives such as herceptin;
 - h) alkylating drugs such as platinum drugs (cis-platin, carboplatin, oxaliplatin, paraplalin) or nitrosoureas;
 - i) drugs potentially affecting metastasis of tumours such as matrix metalloproteinase inhibitors;
 - j) gene therapy and antisense agents;
 - k) antibody therapeutics;

- l) other bioactive compounds of marine origin, notably the didemnins such as aplidine;
- m) steroid analogues, in particular dexamethasone;
- n) anti-inflammatory drugs, in particular dexamethasone; and
- o) anti-emetic drugs, in particular dexamethasone.

In the reaction scheme on page 3, the protecting group TBS and PMB may be replaced by other groups. Examples of hydroxy protecting groups are to be seen, for example, in WO 0069862 at pages 19 and 20. Each of the separate steps in the scheme is a process of this reaction. The groups R shown in the scheme can be varied to other substituents, notably other groups R in the general formula 5 and other hydroxy protecting groups. The group shown as R' in the scheme can also be varied, and be a group R defined in the general formula 5. This terminal substituent can be carried through to the end compounds of this invention, and thus it is not necessary to have an ethyl group at the position alpha to the keto group. Other activating groups in place of the indicated X may be employed. The identity of the compound 9 can be changed to allow for other ways to get from the compound 8 to the compound 11.

THE PATENT OFFICE
20 AUG 2003
Received in Patents
International Unit

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.